Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 96, Issue 1, Pages 91-95Publisher
SPRINGER
DOI: 10.1007/s10549-005-9048-0
Keywords
AKT; breast cancer; erbB2; estrogen receptor; mutations; PI3K; prognosis
Categories
Ask authors/readers for more resources
The phosphatidylinositol-3-kinase (PI3K)-AKT signaling pathway is considered to play an important role in tumorigenesis. Frequent somatic mutations in the PI3K subunit p110 alpha (PIK3CA) occur in a variety of cancer types. We screened 250 primary human breast tumors for mutations in PIK3CA in order to determine associations with pathological features and with patient outcome. The frequency of PIK3CA mutations in the C2, helical and kinase domains was 35% (88/250). Mutations were associated with larger tumor size (p=0.004) and positive estrogen receptor status (p=0.008). Patients with PIK3CA mutations showed significantly worse survival (p=0.004), particularly those with positive estrogen receptor expression or non-amplified erbB2 (both p=0.002). PIK3CA mutation was an independent factor for worse survival in breast cancer patients with non-amplified erbB2 (RR = 2.6, 95% CI [1.2-5.5], p = 0.016).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available